{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:38:06Z","timestamp":1790282286550,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[1999,10]]},"DOI":"10.4065\/74.10.1038","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:16:10Z","timestamp":1232759770000},"page":"1038-1048","source":"Crossref","is-referenced-by-count":5,"title":["Antimycobacterial Therapy"],"prefix":"10.4065","volume":"74","author":[{"given":"Robert E.","family":"Van Scoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad J.","family":"Wilkowske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/74.10.1038_bib1","series-title":"Global Tuberculosis Control: WHO Report 1998","author":"World Health Organization","year":"1998"},{"key":"10.4065\/74.10.1038_bib2","doi-asserted-by":"crossref","first-page":"13881","DOI":"10.1073\/pnas.95.23.13881","article-title":"Modeling the impact of global tuberculosis control strategies","volume":"95","author":"Murray","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4065\/74.10.1038_bib3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1164\/ajrccm.149.5.8173779","article-title":"Treatment of tuberculosis and tuberculosis infection in adults and children","volume":"149","author":"American Thoracic Society and Centers for Disease Control and Prevention","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.4065\/74.10.1038_bib4","author":"Centers for Disease Control and Prevention, Division of Tuberculosis Elimination"},{"issue":"RR-13","key":"10.4065\/74.10.1038_bib5","first-page":"1","article-title":"Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994","volume":"43","author":"Centers for Disease Control and Prevention","year":"1994","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.4065\/74.10.1038_bib6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1164\/ajrccm.154.4.8887600","article-title":"Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis","volume":"154","author":"Moore","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"RR 20","key":"10.4065\/74.10.1038_bib7","first-page":"1","article-title":"Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations","volume":"47","author":"Centers for Disease Control and Prevention","year":"1998","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-4","key":"10.4065\/74.10.1038_bib8","first-page":"1","article-title":"The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices","volume":"45","year":"1996","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.4065\/74.10.1038_bib9","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1164\/ajrccm.155.5.9154896","article-title":"Rapid diagnostic tests for tuberculosis: what is the appropriate use? Am","volume":"155","author":"American Thoracic Society Workshop","year":"1997","journal-title":"J Respir Crit Care Med"},{"key":"10.4065\/74.10.1038_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0025-7125(05)70522-8","article-title":"Nontuberculous mycobacterlal infections","volume":"81","author":"French","year":"1997","journal-title":"Med Clin North Am"},{"key":"10.4065\/74.10.1038_bib11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1164\/ajrccm.156.2.atsstatement","article-title":"Diagnosis and treatment of disease caused by nontuberculous mycobacteria","volume":"156","author":"American Thoracic Society","year":"1997","journal-title":"Am J Crit Care Med"},{"key":"10.4065\/74.10.1038_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1378\/chest.101.6.1605","article-title":"Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: the Lady Windermere syndrome","volume":"101","author":"Reich","year":"1992","journal-title":"Chest"},{"key":"10.4065\/74.10.1038_bib13","first-page":"209","article-title":"Pulmonary infection with Mycobacterium avium-intracellutare: diagnosis, clinical patterns, treatment","volume":"57","author":"Teirstein","year":"1990","journal-title":"Mt Sinai J Med"},{"key":"10.4065\/74.10.1038_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199608083350602","article-title":"A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol. and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin","volume":"335","author":"Shafran","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4065\/74.10.1038_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1056\/NEJM199608083350604","article-title":"Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin. or both","volume":"335","author":"Havlir","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4065\/74.10.1038_bib16","first-page":"922","article-title":"1997 USPHS\/IDSA guidelines for the prevention of opportunistic infections in persons Infected with human immunodeficiency virus","volume":"127","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.4065\/74.10.1038_bib17","first-page":"2264","article-title":"Other Mycobacterium species","volume":"Vol 2","author":"Horowitz","year":"1995"},{"key":"10.4065\/74.10.1038_bib18","first-page":"301","article-title":"New developments in the treatment of nontuberculous mycobacterial (NTM) disease","volume":"11","author":"Griffith","year":"1996","journal-title":"Semin Respir Infect"},{"key":"10.4065\/74.10.1038_bib19","doi-asserted-by":"crossref","first-page":"104108","DOI":"10.1016\/0962-8479(95)90550-2","article-title":"Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy","volume":"76","author":"Sauret","year":"1995","journal-title":"Tuber Lung Dis"},{"key":"10.4065\/74.10.1038_bib20","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/archinte.1994.00420120079009","article-title":"Mycobacterium marinum skin infections: report of 31 cases and review of the literature","volume":"154","author":"Edelstein","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.4065\/74.10.1038_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/00365548709032420","article-title":"Failure of doxycycline treatment in aquarium-associated Mycobacterium marinum infections","volume":"19","author":"Ljungberg","year":"1987","journal-title":"Spend J Infect Dis"},{"key":"10.4065\/74.10.1038_bib22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5694\/j.1326-5377.1992.tb137399.x","article-title":"Mycobacterium marinum infection: epidemiology and presentation in Queensland 1971\u20131990","volume":"157","author":"Iredell","year":"1992","journal-title":"Med J Aust"},{"key":"10.4065\/74.10.1038_bib23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/clinids\/18.4.664","article-title":"Clarithromycin: a potent agent against infections due to Mycobacterium marinum [letter]","volume":"18","author":"Bonnet","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.4065\/74.10.1038_bib24","first-page":"1","volume":"874","author":"WHO Expert Committee on Leprosy","year":"1998","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.4065\/74.10.1038_bib25","series-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","first-page":"1155","article-title":"Drugs used in the chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy","author":"Mandell","year":"1996"},{"key":"10.4065\/74.10.1038_bib26","first-page":"86","article-title":"Isoniazid dosage in patients with renal failure","volume":"289","author":"Bowsraox","year":"1973","journal-title":"N Engl J Med"},{"key":"10.4065\/74.10.1038_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/0003-4819-84-2-181","article-title":"Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis","volume":"84","author":"Mitchell","year":"1976","journal-title":"Ann intern Med"},{"key":"10.4065\/74.10.1038_bib28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-85-3-398_2","article-title":"Preventing isoniazid hepatotoxicity [letter]","volume":"85","author":"Moulding","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.4065\/74.10.1038_bib29","first-page":"171","article-title":"Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis","volume":"1","author":"Hong Kong Chest Service\/British Medical Research Council","year":"1981","journal-title":"Lancet"},{"key":"10.4065\/74.10.1038_bib30","first-page":"97","article-title":"Isoniazid-associated hepatitis: summary of the report of the Tuberculosis Advisory Committee and special consultants to the director, Centers for Disease Control","volume":"23","year":"1974","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.4065\/74.10.1038_bib31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-81-2-200","article-title":"The effect of isoniazid on transaminase levels","volume":"81","author":"Balley","year":"1974","journal-title":"Ann Intern Med"},{"key":"10.4065\/74.10.1038_bib32","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/ajp.125.12.1725","article-title":"Possible interaction between disulfiram and isoniazid","volume":"125","author":"Whittington","year":"1969","journal-title":"Am J Psychiatry"},{"key":"10.4065\/74.10.1038_bib33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.7326\/0003-4819-113-10-799","article-title":"Severe acetaminophen toxicity in a patient receiving isoniazid","volume":"113","author":"Murphy","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.4065\/74.10.1038_bib34","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1001\/archinte.1997.00440420085007","article-title":"Update on rifampin drug interactions. III","volume":"157","author":"Strayhorn","year":"1997","journal-title":"Arch intern Med"},{"key":"10.4065\/74.10.1038_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/bmj.3.5770.343","article-title":"Potentially serious side effects of high-dose twice-weekly rifampicin","volume":"3","author":"Poola","year":"1971","journal-title":"BMJ"},{"key":"10.4065\/74.10.1038_bib36","first-page":"693","article-title":"Uveitis associated with rifabutin therapy: a clinical alert","volume":"67","author":"Petrowski","year":"1996","journal-title":"J Am Optom Assoc"},{"key":"10.4065\/74.10.1038_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0041-3879(77)90022-8","article-title":"The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazmamide","volume":"59","author":"Girling","year":"1978","journal-title":"Tubercle"},{"key":"10.4065\/74.10.1038_bib38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/thx.41.10.737","article-title":"Ocular toxicity from ethambutol [editorial]","volume":"41","author":"Citron","year":"1986","journal-title":"Thorax"},{"key":"10.4065\/74.10.1038_bib39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0025-6196(11)65134-3","article-title":"The aminoglyeosides","volume":"74","author":"Edson","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/74.10.1038_bib40","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0025-6196(11)64003-2","article-title":"The fluoroquinolones","volume":"74","author":"Walker","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/74.10.1038_bib41","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/74.7.730","article-title":"Trimethoprim-sulfamethoxazole","volume":"74","author":"Smilack","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/74.10.1038_bib42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4065\/74.7.727","article-title":"The tetracyclines","volume":"74","author":"Smilack","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/74.10.1038_bib43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4065\/74.6.613","article-title":"The macrolides: erythromycin, clarithromycin, and azithromycin","volume":"74","author":"Alvarez-Elcoro","year":"1999","journal-title":"Mayo Clin Proc"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611640044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611640044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T01:11:01Z","timestamp":1589505061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611640044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["S0025619611640044"],"URL":"https:\/\/doi.org\/10.4065\/74.10.1038","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[1999,10]]}}}